Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Current Deferred Revenue (2020 - 2025)

Cytosorbents (CTSO) has disclosed Current Deferred Revenue for 7 consecutive years, with $403000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Deferred Revenue changed N/A year-over-year to $403000.0, compared with a TTM value of $403000.0 through Sep 2025, changed N/A, and an annual FY2024 reading of $596000.0, down 56.84% over the prior year.
  • Current Deferred Revenue was $403000.0 for Q3 2025 at Cytosorbents, up from $361000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $1.9 million in Q4 2021 and bottomed at $361000.0 in Q2 2025.
  • Average Current Deferred Revenue over 5 years is $964424.9, with a median of $596000.0 recorded in 2024.
  • The sharpest move saw Current Deferred Revenue surged 167.36% in 2021, then plummeted 56.84% in 2024.
  • Year by year, Current Deferred Revenue stood at $1.9 million in 2021, then decreased by 22.11% to $1.5 million in 2022, then fell by 8.96% to $1.4 million in 2023, then plummeted by 56.84% to $596000.0 in 2024, then plummeted by 32.38% to $403000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for CTSO at $403000.0 in Q3 2025, $361000.0 in Q2 2025, and $546028.0 in Q1 2025.